71.53

0.10% -0.07

Pre-market: 72.41 0.88 +1.23%

Halozyme Therapeutics Inc (HALO)

Overview News Price History Option Chain Financials Why HALO Down? Discussions Forecast

Halozyme Therapeutics Inc stock is traded at $71.53, with a volume of 1.14M. It is down -0.10% in the last 24 hours and up +8.59% over the past month. Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Previous Close:

$71.60

Open:

$71.725

24h Volume:

1.14M

Relative Volume:

0.70

Market Cap:

$8.48B

Revenue:

$1.40B

Net Income/Loss:

$316.89M

P/E Ratio:

28.71

EPS:

2.4918

Net Cash Flow:

$644.59M

1W Performance:

+7.50%

1M Performance:

+8.59%

6M Performance:

+12.95%

1Y Performance:

+33.58%

1-Day Range:

$70.71

$72.25

1-Week Range:

$65.59

$72.25

52-Week Range:

$51.06

$82.22

Halozyme Therapeutics Inc Stock (HALO) Company Profile

Name

Halozyme Therapeutics Inc

Sector

Healthcare (1101)

Industry

Biotechnology (614)

Phone

(858) 794-8889

Address

12390 EL CAMINO REAL, SAN DIEGO, CA

Employee

423

Twitter

@halozymeinc

Next Earnings Date

2026-05-11

Latest SEC Filings

HALO's Discussions on Twitter

Compare HALO vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
HALO Halozyme Therapeutics Inc	71.53	8.49B	1.40B	316.89M	644.59M	2.4918
VRTX Vertex Pharmaceuticals Inc	446.83	112.12B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	635.45	65.92B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	891.32	52.38B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	303.05	40.54B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	149.23	33.10B	742.00K	-1.37B	-1.07B	-7.0731

Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-04-25	Downgrade	Goldman	Neutral → Sell
Oct-14-25	Upgrade	Leerink Partners	Underperform → Market Perform
Aug-06-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jul-10-25	Resumed	Goldman	Neutral
May-14-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
May-13-25	Downgrade	Leerink Partners	Market Perform → Underperform
Oct-07-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Sep-19-24	Downgrade	JP Morgan	Overweight → Neutral
Jun-07-24	Downgrade	Piper Sandler	Overweight → Neutral
Feb-29-24	Initiated	TD Cowen	Outperform
Jul-24-23	Downgrade	Goldman	Buy → Neutral
Jul-24-23	Initiated	H.C. Wainwright	Buy
May-10-23	Upgrade	Piper Sandler	Neutral → Overweight
Mar-27-23	Resumed	Berenberg	Buy
Mar-16-23	Downgrade	SVB Securities	Outperform → Market Perform
Dec-21-22	Resumed	Morgan Stanley	Overweight
Nov-28-22	Initiated	Wells Fargo	Overweight
Sep-09-22	Initiated	Morgan Stanley	Overweight
May-23-22	Initiated	SVB Leerink	Outperform
Jun-14-21	Initiated	Evercore ISI	Outperform
May-17-21	Initiated	SVB Leerink	Outperform
May-11-21	Downgrade	Piper Sandler	Overweight → Neutral
Jan-21-21	Reiterated	The Benchmark Company	Buy
Dec-17-20	Initiated	Berenberg	Buy
Sep-14-20	Resumed	JP Morgan	Overweight
Jul-01-20	Initiated	The Benchmark Company	Buy
Feb-05-20	Upgrade	Piper Sandler	Neutral → Overweight
Jan-09-20	Upgrade	BMO Capital Markets	Market Perform → Outperform
Jan-08-20	Initiated	Goldman	Buy
Nov-05-19	Upgrade	Barclays	Underweight → Equal Weight
Oct-19-18	Resumed	Piper Jaffray	Neutral
May-11-18	Downgrade	Barclays	Equal Weight → Underweight
Jan-24-18	Initiated	Goldman	Neutral
Oct-16-17	Reiterated	Piper Jaffray	Overweight
Jan-06-17	Downgrade	Citigroup	Buy → Neutral
Nov-03-16	Initiated	Deutsche Bank	Buy
Dec-04-15	Initiated	Wells Fargo	Outperform
Nov-18-15	Initiated	Citigroup	Buy
Sep-22-15	Initiated	Barclays	Overweight
Jun-22-15	Reiterated	JP Morgan	Overweight
Mar-03-15	Reiterated	UBS	Buy
Feb-18-15	Reiterated	MLV & Co	Buy
Jan-08-15	Reiterated	MLV & Co	Buy

View All

Halozyme Therapeutics Inc Stock (HALO) Latest News

Jun 06, 2026

Quick ratio of Halozyme Therapeutics, Inc. – XETR:RV7 - TradingView

Jun 06, 2026

A Look At Halozyme Therapeutics (HALO) Valuation After New ENHANZE Data And Analyst Buy Reaffirmation - Sahm

Jun 06, 2026

ETFs Investing in Halozyme Therapeutics, Inc. Stocks - TradingView

Jun 06, 2026

Halozyme Therapeutics, Inc. Income Statement – XETR:RV7 - TradingView

Jun 06, 2026

Jun 05, 2026

Halozyme licenses Hypercon technology to Oruka for psoriasis drug - Investing.com

Jun 05, 2026

Jun 04, 2026

How New ENHANZE Data And Analyst Support At Halozyme Therapeutics (HALO) Has Changed Its Investment Story - Yahoo Finance

Jun 04, 2026

Halozyme Therapeutics(HALO.US) Officer Sells US$3.37 Million in Common Stock - Moomoo

Jun 04, 2026

Jun 03, 2026

Halozyme CEO Helen Torley sells $3.37m in shares after exercising options By Investing.com - Investing.com South Africa

Jun 03, 2026

Halozyme Therapeutics Stock Gains 5.2% on Analyst Buy Rating and argenx Data NewsNews and Statistics - IndexBox

Jun 03, 2026

Halozyme CEO Helen Torley sells $3.37m in shares after exercising options - Investing.com

Jun 03, 2026

Why Is Halozyme Therapeutics (HALO) Stock Rocketing Higher Today - Yahoo Finance

Jun 03, 2026

Halozyme (NASDAQ: HALO) CEO sells 50K shares after exercising 50K options - Stock Titan

Jun 03, 2026

Halozyme Therapeutics Jumps 5.4% Amid Sector-Wide Rally - AlphaStreet

Jun 03, 2026

Benchmark reiterates Halozyme stock Buy rating on long-term potential - Investing.com

Jun 03, 2026

Benchmark reiterates Halozyme stock Buy rating on long-term potential By Investing.com - Investing.com Canada

Jun 03, 2026

Halozyme Therapeutics Inc (NASDAQ:HALO): A Deep Value Play Combining Strong Profitability with an Attractive 14.35 P/E - ChartMill

Jun 03, 2026

Insider Sell Alert: Bernadette Connaughton Sells Shares of Haloz - GuruFocus

Jun 03, 2026

Jun 02, 2026

Insider Sell Alert: Bernadette Connaughton Sells Shares of Halozyme Therapeutics Inc (HALO) - GuruFocus

Jun 02, 2026

Director at Halozyme (NASDAQ: HALO) sells shares under Rule 10b5-1 plan - Stock Titan

Jun 02, 2026

HALO Stock Chart | HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - ChartMill

Jun 02, 2026

Jun 01, 2026